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a  b  s  t  r  a  c  t
Renal disease secondary to vasculitis associated with anti-neutrophil cytoplasmic antibod-
ies  (ANCA) can lead to chronic renal disease requiring renal replacement therapy. In these
patients, kidney transplantation offers excellent long-term rates of allograft and patient
survival; consequently, they can be trasplanted when the clinical disease activity has remit-
ted.  However, the risk of disease relapses in the renal allograft remains, although at lower
rates due to modern immunosuppressive regimes. We describe the case of a male patient
with  extracapillary glomerulonephritis type III C-ANCA (+) who developed a recurrence in
the renal allograft 8 years after transplantation. Intensive immunosupression with plasma-
pheresis controlled the disease.
©  2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recidiva  de  vasculitis  asociada  a  anticuerpos  anticitoplasma  de
neutróﬁlos  en  un  paciente  con  trasplante  renal
r  e  s  u  m  e  nPalabras clave:
Vasculitis asociada a anticuerpos
anticitoplasma de neutróﬁlos
La afectación renal de las vasculitis asociadas a anticuerpos anticitoplasma de neutróﬁlos
(ANCA) puede conducir a enfermedad renal crónica con necesidad de tratamiento renal
sustitutivo. En estos enfermos el trasplante renal ofrece excelentes tasas de superviven-
Trasplante renal
Recidiva
cia  del injerto y del receptor a largo plazo, por lo que pueden ser trasplantados cuando la
enfermedad está en remisión. Sin embargo, la amenaza de recidivas de la enfermedad en el
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injerto se mantiene, aunque, con las modernas pautas de inmunosupresión, su incidencia
es  menor. Presentamos el caso de un varón diagnosticado de glomerulonefritis extracapilar
tipo III C-ANCA (+) que desarrolló una recidiva de la enfermedad en el injerto renal 8 an˜os
después de ser trasplantado. La intensiﬁcación de la inmunosupresión con plasmaféresis
consiguió controlar la enfermedad.
© 2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un








































urrently, extracapillary glomerulonephritis type III with the
emonstration of cytoplasmic antibodies (ANCA) is part of one
f the three variants of ANCA-associated vasculitis (AAV) but
ffecting the kidneys only. The other two would be granu-
omatosis with polyangiitis (Wegener’s granulomatosis) and
icroscopic polyangiitis.1 These vasculitis are the most fre-
uent cause of rapidly progressive glomerulonephritis. With
arly diagnosis and the application of therapy, based mainly
n steroids and cyclophosphamide, the survival of patients
nd preservation of renal function is improved. However, more
han 20% of these patients, develop end-stage renal disease,
equiring renal replacement therapy.2–4
In these patients, renal transplantation is an alternative
hat provides excellent results, still there are issues that have
o be resolved.4–6 First, due to the possibility of recurrence
f the disease in the graft,6–11 it is not clear when would be
he most appropriate time to include patients on the trans-
lant waiting list. Second, there is no clear agreement on the
reatment of recurrences.12
We  report the case of a patient with Type III extracapillary
lomerulonephritis associated with anti-proteinase 3 ANCA
C-ANCA) who,  after 8 years of cadaver kidney graft transplant,
ad a recurrence of the disease in the graft. Concerning the
ase, a brief review of the subject has been included.
linical  case
 60-year-old male diagnosed in another hospital in 2000
f C-ANCA associated Type III extracapillary glomeru-
onephritis. He was treated with 5 intravenous bolus of
-methylprednisolone followed by oral corticosteroids in
ecreasing doses associated to oral cyclophosphamide (unable
o obtain information about exact dosing). At one point,
yclophosphamide was discontinued due to myelotoxicity.
In 2002 the patient was included in a regular haemodialysis
rogram.
In September 2006, he received a cadaver kidney graft
n another transplant center. The patient was receiving
acrolimus monotherapy, although we cannot rule out hav-
ng received some other combination of immunosuppressant
herapy. Serum creatinine levels ranged from 1.5 to 1.7 mg/dl.In December 2013, during the implantation of a percuta-
eous aortic valve in our hospital, a pre and post-intervention
linical evaluation was carried out in our department. At
hat time his clinical condition was satisfactory, with serum(http://creativecommons.org/licenses/by-nc-nd/4.0/).
creatinine level of 1.5 mg/dl and proteinuria 0.3 g/day, with a
normal urinary sediment.
In October 2014, due to onset of respiratory symptoms
with fever and impaired renal function, the patient requested
to be transferred to our hospital for clinical follow-up. He
had absence of microbiological and radiologic infections; he
improved after empirical treatment with levoﬂoxacin. How-
ever in a few days, renal function deteriorated reaching
serum creatinine levels of 4 mg/dl with proteinuria of 6.8 g/day
accompanied by haematuria. Determination of C-ANCA was
74.2 IU/ml (normal range: 0–5 IU ml)  and P-ANCA 8.4 IU/ml
(normal range: 0–6 IU/ml). The other autoimmunity parame-
ters (ANA, anti-GBM antibodies, complement, cryoglobulins,
etc.) were negative. HIV, HCV, HBV serology, and CMV  and BK
viremia were also negative.
A renal graft biopsy was performed and the most rele-
vant ﬁndings were (Fig. 1): 3 out of the 19 evaluable glomeruli
had global glomerular sclerosis, and 12 glomeruli had cellular
crescents. Some of them had Bowman’s capsule disrup-
tion causing pseudo-granulomatous inﬂammatory reaction of
mononuclear cells. Two glomeruli had injuries consistent with
ﬁbrinoid necrosis. We  found tubular necrosis in 15%, tubu-
lar atrophy 20% and some casts, plus interstitial inﬁltration
in 25% with some eosinophils and foci of recent intersti-
tial hemorrhage and arteriolar hyalinosis, with some images
of wall mucoid degeneration without transmural inﬁltrate.
Immunoﬂuorescence study was negative. Immunohistochem-
istry for C4d was negative.
Given the evidence of a recurrence of the underlying dis-
ease, the patient received 3 intravenous bolus of 500 mg
of 6-methylprednisolone (the patient was diabetic) on con-
secutive days, followed by oral prednisone at a dose of
0.5 mg/kg/day in descending dosing. Likewise, 8 sessions
of plasmapheresis were applied, and we started treatment
with mycophenolate mofetil (1 g/12 h, orally) associated with
tacrolimus.
Twelve days after admission, the patient was discharged
with a serum creatinine level of 2.9 mg/dl. In an outpatient
check-up a month later, creatinine level was of 2.3 mg/dl with
proteinuria of 3.6 g/day.
Discussion
Treatment of AAV is based mainly on the association
of cyclophosphamide and corticosteroids; this therapy has
shown clear efﬁcacy in improving patient survival and preser-
vation of renal function. However, more  than 20% of patients
develop end stage renal disease requiring renal replacement
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Fig. 1 – Renal biopsy: (a) hematoxylin–eosin, (b) PAS, (c) methenamine silver stain, (d) Masson’s trichrome showing the
presence of cellular crescents in 12 out of the 19 evaluable glomeruli, with injuries in 2 glomeruli compatible with ﬁbrinoid
necrosis.therapy.2–4 In these patients, renal transplantation is an excel-
lent alternative since it achieves graft survival rates of 90% for
5 years and about 70% for 10 years, with recipient survival of
65% for 10 years and an average survival of 13.4 years. These
are a very positive data in comparison to transplanted patients
with other types of renal diseases.4–6
The recurrence nature of the disease is a threat to patients.
Recent studies compare rates of disease recurrence with
different immunosuppressive regimens; Rituximab versus
cyclophosphamide associated with corticoids, the reported
recurrence rates are 32% with cyclophosphamide and 29%
with rituximab at 18 months.13,14
Once patients receive a transplant, the risk of disease
recurrence persists. The information we have comes from
isolated cases or small series from some centers, still the
collection of available data shows that the incidence of recur-
rence of the disease has decreased as immunosuppression
therapy has changed. In 1999, Nachman et al., reviewed 127
published cases and found a recurrence rate of 17%, with
31 months mean time from transplant to recurrence (range
from 5 days to 13 years).7 It is important to note that, in
these cases the immunosuppressive regime was based largely
in cyclosporine A. In consecutive years, with more  actual
guidelines on immunosuppression, and with the use of anti-
body induction, corticosteroids, mofetil mycophenolate and
tacrolimus, the recurrence rates are apparently lower. Thesevary depending on the series: 8.6% (Gera et al., 2007),8 4.7%
(Little et al., 2009)9 and 8.2% (Geetha et al., 2011).10 It is very
likely that the introduction of these drugs to control cellular
and humoral immune responses in the transplant has con-
tributed signiﬁcantly in reducing recurrence rates. In fact,
thymoglobulin has been used. It is being suggested the use
thymoglobulin or mofetil mycophenolate to control vasculi-
tis activity in certain cases of resistance or intolerance to
cyclophosphamide.15,16
This patient experienced a recurrence of the disease in
the kidney graft after 8 years transplantation. Although we
have been unable to collect complete patient information
as he received the transplant at another facility, it seems
that vasculitis activity was controlled given that a year ear-
lier, at our center, there was no evidence of disease activity.
The reason for initiating an immunosuppressant monother-
apy with Tacrolimus was not known. It could have had some
involvement in the onset of disease recurrence. Therefore, we
venture to point out that in these conditions, any changes
in immunosuppressive maintenance regime should be espe-
cially weighed and pondered.
Another aspect for consideration would be the moment in
which patients should be included in the waiting list for renal
transplantation. Although some authors point to the desir-
ability of waiting a year once remission has occurred, as in
other related diseases, there seems to be a consensus that
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atients is ready to receive a transplant once the disease is
n complete remission, meaning that there is a total absence
f symptoms.8,9,11 Although it should be noted that, in the
eview by Little et al., renal transplants performed within a
ear of remission of the disease is a risk factor for mortality
HR 2.3; p = 0.04).9
The persistence of detectable ANCA does not mean that the
isease is active, in fact, ANCA status is not included either in
ersion 3 of the Birmingham Vasculitis Activity Score (BVAS) or the
ost recent deﬁnition of the European Vasculitis Study Group.17
uillevin et al. in a recent study described ANCA positivity
n 62% (IFA) or 46% (ELISA) of patients already considered in
emission.17 Similarly, a signiﬁcant part of transplant patients,
n some series by more  than 40%, are ANCA (+) at the time of
ransplantation.7–9 Moreover, ANCA status at the moment of
ransplantation doesn’t predict the likelihood of relapse, nor
he prognosis of the graft or the patient survival. The type of
NCA (myeloperoxidase or antiproteinase-3) does not predict
utcome, although in some work it has been shown an associ-
tion between the type of ANCA and the development of graft
asculopathy.9
Due to the scarcity of cases and the wide dispersion it is
ifﬁcult to establish standard treatment guidelines for AAV
ecurrence in patients with renal transplantation and, there-
ore, to draw relevant conclusions. Moreover, when deciding
he intensity of the treatment, it is important to consider the
everity of recurrence using some criteria such as, Birming-
am Vasculitis Activity Score.
The medical treatment used in the reported cases is
iverse. It includes the reintroduction of cyclophosphamide,
lasmapheresis sessions, steroid bolus, intensiﬁcation of
asal immunosuppression, etc.12,18,19 As indicated earlier, we
elieve that the results cannot be quantiﬁed accurately. In
ecent years, the successful introduction of rituximab, not
nly for the induction of disease remission but also to control
ecurrences, opens up new possibilities in AAV17 treatment.
ts application has not been tested in transplant patients.
In our case, we  chose to intensify immunosuppres-
ion through the administration of corticosteroids after
-methylprednisolone bolus, the administration of mofetil
ycophenolate, and maintaining tacrolimus with plasma-
heresis sessions. This treatment resulted in a short term
ontrol of renal disease.
To resume, we describe the case of a patient with a recur-
ence of a AAV variant that was controlled, short-term, with
he intensiﬁcation of immunosuppression and plasmaphere-
is. For patients with end stage renal failure secondary to
AV, renal transplantation provides excellent results and
hould be considered once remission is established. The
ossibility of recurrence of the disease exists, although the
ate of recurrence is decreasing, probably due to modern
mmunosuppressive drugs. The addition of Rituximab to more
onventional treatments adds optimism to disease control.onﬂict  of  interest
he authors informed that they had no conﬂict of interest.
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